Home  |  Privacy Policy  |  Terms and Conditions  |  Contact Medical Information  |  Site Map

Clinical Information About Pulmonary Arterial Hypertension Associated with Scleroderma Spectrum of Diseases (PAH/SSD)

Study Design in PAH/SSD1

These results are from a 12-week, prospective, open-label, randomized trial. Except for 5 NYHA Functional Class II patients, all patients were either Functional Class III or IV. In this clinical trial, patients received chronic continuous infusions of epoprostenol plus conventional therapy (n=56) or conventional therapy alone (n=55). Conventional therapy could include anticoagulants, oral vasodilators, supplemental oxygen, digoxin, and/or diuretics.

Read about exercise data in PAH/SSD